Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
62
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yale University

Collaborators